BETHESDA, MD — April 23, 2002 — The first major National Institutes of Health (NIH) clinical trial for dialysis in over 20 years confirms that the minimum dose recommended by treatment guidelines is adequate and, in general, a higher dose and special filters provide no added benefit to patients.
High death rates and frequent hospitalizations among hemodialysis patients was the major impetus for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to fund the landmark Hemodialysis (HEMO) Study.
People who received a dialysis dose higher than the minimum recommended or who used high-flux filters neither lived longer nor stayed out of the hospital longer than people who received the standard dose or used low-flux filters, announced lead HEMO Study investigator Garabed Eknoyan at a National Kidney Foundation (NKF) meeting in Chicago on Sunday. This will be welcome news to hundreds of thousands of people in the United States who undergo hemodialysis, since the results support clinical practice guidelines from NKF's Kidney Disease Outcomes Quality Initiative (K/DOQI).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!